323 related articles for article (PubMed ID: 33357483)
1. Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study.
den Boer ML; Cario G; Moorman AV; Boer JM; de Groot-Kruseman HA; Fiocco M; Escherich G; Imamura T; Yeoh A; Sutton R; Dalla-Pozza L; Kiyokawa N; Schrappe M; Roberts KG; Mullighan CG; Hunger SP; Vora A; Attarbaschi A; Zaliova M; Elitzur S; Cazzaniga G; Biondi A; Loh ML; Pieters R;
Lancet Haematol; 2021 Jan; 8(1):e55-e66. PubMed ID: 33357483
[TBL] [Abstract][Full Text] [Related]
2. Tyrosine kinase inhibitor response of ABL-class acute lymphoblastic leukemia: the role of kinase type and SH3 domain.
van Outersterp I; Tasian SK; Reichert CEJ; Boeree A; de Groot-Kruseman HA; Escherich G; Boer JM; den Boer ML
Blood; 2024 May; 143(21):2178-2189. PubMed ID: 38394665
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia.
Boer JM; Steeghs EM; Marchante JR; Boeree A; Beaudoin JJ; Beverloo HB; Kuiper RP; Escherich G; van der Velden VH; van der Schoot CE; de Groot-Kruseman HA; Pieters R; den Boer ML
Oncotarget; 2017 Jan; 8(3):4618-4628. PubMed ID: 27894077
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant tyrosine kinase inhibitor therapy improves outcome for children and adolescents with acute lymphoblastic leukaemia who have an ABL-class fusion.
Moorman AV; Schwab C; Winterman E; Hancock J; Castleton A; Cummins M; Gibson B; Goulden N; Kearns P; James B; Kirkwood AA; Lancaster D; Madi M; McMillan A; Motwani J; Norton A; O'Marcaigh A; Patrick K; Bhatnagar N; Qureshi A; Richardson D; Stokley S; Taylor G; van Delft FW; Moppett J; Harrison CJ; Samarasinghe S; Vora A
Br J Haematol; 2020 Dec; 191(5):844-851. PubMed ID: 32926422
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic Hematopoietic Stem Cell Transplantation, Especially Haploidentical, May Improve Long-Term Survival for High-Risk Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Tyrosine Kinase Inhibitor Era.
Xue YJ; Cheng YF; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Sun YQ; Suo P; Chen YH; Chen H; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Huang XJ
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1611-1620. PubMed ID: 30537550
[TBL] [Abstract][Full Text] [Related]
6. Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols.
Cario G; Leoni V; Conter V; Attarbaschi A; Zaliova M; Sramkova L; Cazzaniga G; Fazio G; Sutton R; Elitzur S; Izraeli S; Lauten M; Locatelli F; Basso G; Buldini B; Bergmann AK; Lentes J; Steinemann D; Göhring G; Schlegelberger B; Haas OA; Schewe D; Buchmann S; Moericke A; White D; Revesz T; Stanulla M; Mann G; Bodmer N; Arad-Cohen N; Zuna J; Valsecchi MG; Zimmermann M; Schrappe M; Biondi A
Haematologica; 2020 Jul; 105(7):1887-1894. PubMed ID: 31601692
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial.
Parker C; Krishnan S; Hamadeh L; Irving JAE; Kuiper RP; Révész T; Hoogerbrugge P; Hancock J; Sutton R; Moorman AV; Saha V
Lancet Haematol; 2019 Apr; 6(4):e204-e216. PubMed ID: 30826273
[TBL] [Abstract][Full Text] [Related]
8. Characterization of pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia with kinase fusions in Japan.
Imamura T; Kiyokawa N; Kato M; Imai C; Okamoto Y; Yano M; Ohki K; Yamashita Y; Kodama Y; Saito A; Mori M; Ishimaru S; Deguchi T; Hashii Y; Shimomura Y; Hori T; Kato K; Goto H; Ogawa C; Koh K; Taki T; Manabe A; Sato A; Kikuta A; Adachi S; Horibe K; Ohara A; Watanabe A; Kawano Y; Ishii E; Shimada H
Blood Cancer J; 2016 May; 6(5):e419. PubMed ID: 27176795
[TBL] [Abstract][Full Text] [Related]
9. SFPQ-ABL1-positive B-cell precursor acute lymphoblastic leukemias.
Biloglav A; Olsson-Arvidsson L; Theander J; Behrendtz M; Castor A; Johansson B
Genes Chromosomes Cancer; 2020 Sep; 59(9):540-543. PubMed ID: 32306475
[TBL] [Abstract][Full Text] [Related]
10. Superior survival of unmanipulated haploidentical haematopoietic stem cell transplantation compared with intensive chemotherapy as post-remission treatment for children with very high-risk philadelphia chromosome negative B-cell acute lymphoblastic leukaemia in first complete remission.
Xue YJ; Suo P; Huang XJ; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Kong J; Zhang XH; Chen YH; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Cheng YF
Br J Haematol; 2020 Mar; 188(5):757-767. PubMed ID: 31725190
[TBL] [Abstract][Full Text] [Related]
11. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia.
Spinelli O; Peruta B; Tosi M; Guerini V; Salvi A; Zanotti MC; Oldani E; Grassi A; Intermesoli T; Micò C; Rossi G; Fabris P; Lambertenghi-Deliliers G; Angelucci E; Barbui T; Bassan R; Rambaldi A
Haematologica; 2007 May; 92(5):612-8. PubMed ID: 17488684
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia.
Tran TH; Harris MH; Nguyen JV; Blonquist TM; Stevenson KE; Stonerock E; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJG; Reshmi SC; Neuberg DS; Sallan SE; Loh ML; Silverman LB
Blood Adv; 2018 Mar; 2(5):529-533. PubMed ID: 29507076
[TBL] [Abstract][Full Text] [Related]
13. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.
Rubnitz JE; Inaba H; Dahl G; Ribeiro RC; Bowman WP; Taub J; Pounds S; Razzouk BI; Lacayo NJ; Cao X; Meshinchi S; Degar B; Airewele G; Raimondi SC; Onciu M; Coustan-Smith E; Downing JR; Leung W; Pui CH; Campana D
Lancet Oncol; 2010 Jun; 11(6):543-52. PubMed ID: 20451454
[TBL] [Abstract][Full Text] [Related]
14. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study.
Biondi A; Schrappe M; De Lorenzo P; Castor A; Lucchini G; Gandemer V; Pieters R; Stary J; Escherich G; Campbell M; Li CK; Vora A; Aricò M; Röttgers S; Saha V; Valsecchi MG
Lancet Oncol; 2012 Sep; 13(9):936-45. PubMed ID: 22898679
[TBL] [Abstract][Full Text] [Related]
15. Beneficial tyrosine kinase inhibitor therapy in a patient with relapsed BCR-ABL1-like acute lymphoblastic leukemia with CCDC88C-PDGFRB fusion.
Oya S; Morishige S; Ozawa H; Sasaki K; Semba Y; Yamasaki Y; Nakamura T; Aoyama K; Seki R; Mouri F; Osaki K; Miyamoto T; Maeda T; Nagafuji K
Int J Hematol; 2021 Feb; 113(2):285-289. PubMed ID: 32951102
[TBL] [Abstract][Full Text] [Related]
16. Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors: A Registry-Based Study of the Italian Blood and Marrow Transplantation Society (GITMO).
Candoni A; Rambaldi A; Fanin R; Velardi A; Arcese W; Ciceri F; Lazzarotto D; Lussana F; Olivieri J; Grillo G; Parma M; Bruno B; Sora F; Bernasconi P; Saccardi R; Foà R; Sessa M; Bresciani P; Giglio F; Picardi A; Busca A; Sica S; Perruccio K; Zucchetti E; Diral E; Iori AP; Colombo AA; Tringali S; Santarone S; Irrera G; Mancini S; Zallio F; Malagola M; Albano F; Carella AM; Olivieri A; Tecchio C; Dominietto A; Vacca A; Sorasio R; Orciuolo E; Risitano AM; Leotta S; Cortelezzi A; Mammoliti S; Oldani E; Bonifazi F;
Biol Blood Marrow Transplant; 2019 Dec; 25(12):2388-2397. PubMed ID: 31400502
[TBL] [Abstract][Full Text] [Related]
17. BCR-ABL1-like acute lymphoblastic leukaemia: From bench to bedside.
Boer JM; den Boer ML
Eur J Cancer; 2017 Sep; 82():203-218. PubMed ID: 28709134
[TBL] [Abstract][Full Text] [Related]
18. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study.
Den Boer ML; van Slegtenhorst M; De Menezes RX; Cheok MH; Buijs-Gladdines JG; Peters ST; Van Zutven LJ; Beverloo HB; Van der Spek PJ; Escherich G; Horstmann MA; Janka-Schaub GE; Kamps WA; Evans WE; Pieters R
Lancet Oncol; 2009 Feb; 10(2):125-34. PubMed ID: 19138562
[TBL] [Abstract][Full Text] [Related]
19. Low incidence of ABL-class and JAK-STAT signaling pathway alterations in uniformly treated pediatric and adult B-cell acute lymphoblastic leukemia patients using MRD risk-directed approach - a population-based study.
Norvilas R; Dirse V; Semaskeviciene R; Mickeviciute O; Gineikiene E; Stoskus M; Vaitkeviciene G; Rascon J; Griskevicius L
BMC Cancer; 2021 Mar; 21(1):326. PubMed ID: 33781217
[TBL] [Abstract][Full Text] [Related]
20. EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications.
Schwab C; Ryan SL; Chilton L; Elliott A; Murray J; Richardson S; Wragg C; Moppett J; Cummins M; Tunstall O; Parker CA; Saha V; Goulden N; Vora A; Moorman AV; Harrison CJ
Blood; 2016 May; 127(18):2214-8. PubMed ID: 26872634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]